Argenx SE stock draws spotlight as top biotech pick amid Vyvgart expansion and strong Q4 momentum

Argenx SE (ISIN: NL0010832176), the Netherlands-based biotech leader in autoimmune therapies, gains traction as analysts highlight Vyvgart's growth potential following robust Q4 2025 results. DACH investors eye pipeline catalysts in a volatile sector.

Argenx SE has emerged as a standout in the biotech sector, listed on Nasdaq under ticker ARGX with ISIN NL0010832176. The company's shares are drawing fresh attention on March 17, 2026, after being flagged among top biotech stocks to watch, fueled by ongoing Vyvgart expansion and recent analyst upgrades. For DACH investors, this matters now due to Europe's biotech funding challenges and Argenx's strong revenue trajectory in autoimmune treatments, offering a hedge against regional market volatility.

As of: 17.03.2026

By Dr. Elena Voss, Senior Biotech Analyst – Tracking immunology breakthroughs like Argenx's efgartigimod platform amid Europe's push for innovative therapies.

Recent Biotech Spotlight Signals Market Confidence

Argenx SE appeared in MarketBeat's list of top biotech stocks to follow on March 17, 2026, alongside names like CRISPR Therapeutics and Vertex Pharmaceuticals. This recognition underscores investor interest in Argenx's pipeline, particularly efgartigimod (marketed as Vyvgart), targeting severe autoimmune diseases such as myasthenia gravis and immune thrombocytopenia. The Nasdaq-listed shares reflect growing optimism around clinical readouts and commercial uptake.

Vyvgart's Q4 2025 revenues hit $1.29 billion, up 74% year-over-year, surpassing expectations. Analysts at Oppenheimer raised their price target to $1,060 from $1,040, citing myositis data as a potential unlock for 20,000 additional patients. BofA Securities also lifted its target to $1,013, naming Argenx a top pick.

Core Business: Antibody Therapies for Autoimmune Diseases

Argenx SE, headquartered in the Netherlands, focuses on discovering, developing, and commercializing antibody-based therapies for severe autoimmune conditions. Its lead asset, Vyvgart, inhibits the neonatal Fc receptor to reduce harmful antibodies, approved for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in key markets including the US, Europe, and Japan.

The pipeline extends to thyroid eye disease, bullous pemphigoid, and myositis, with empasiprubart and ARGX-119 in late-stage trials for multifocal motor neuropathy and amyotrophic lateral sclerosis. This immunology-centric approach differentiates Argenx in a crowded biotech field, emphasizing neonatal Fc modulation over broad immunosuppression.

Commercial execution has accelerated, with Vyvgart sales demonstrating pricing power and patient adherence in launched indications. European reimbursement progress supports sustained growth, critical for DACH exposure.

Financial Momentum from Q4 Beats and Guidance

Argenx reported Q4 2025 EPS of $8.02, well above the $5.95 consensus, with revenues at $1.29 billion versus $1.28 billion expected. This performance highlights Vyvgart's launch trajectory and operational efficiency, even as R&D investments ramp for pipeline advancement.

Gross margins remain robust in the biotech norm, supported by scalable manufacturing and partnerships like those with AbbVie for ENHANZE delivery tech. Cash position sustains multi-year runway, mitigating dilution risks common in growth-stage biotechs.

Analyst consensus points to continued upside, with Vyvgart projected to expand addressable market through label extensions. For Nasdaq ARGX shares, this translates to potential re-rating if Q1 2026 previews align with flat sales expectations.

Pipeline Catalysts Drive Long-Term Value

Key upcoming milestones include myositis readout in Q3 2026, potentially adding $2-3 billion in peak sales via 20,000 patients. Thyroid eye disease and pemphigus filings follow, targeting orphan designations with premium pricing.

ARGX-119 targets congenital myasthenic syndromes, addressing unmet needs in neuromuscular disorders. Empasiprubart's multifocal motor neuropathy data could open neurology expansion, diversifying beyond immunology.

Regulatory pathways in Europe and Japan favor Argenx's data package, with EMA and PMDA engagements ongoing. Success here amplifies global footprint, crucial for scaling beyond US dominance.

Investor Relevance in a Volatile Biotech Landscape

DACH investors find Argenx compelling due to its European roots and Nasdaq liquidity, blending home bias with US growth exposure. The stock's inclusion in the Nasdaq Biotechnology Index provides benchmark stability amid sector swings.

With biotech valuations compressed post-2025 rate hikes, Argenx's 74% revenue growth offers asymmetry. Portfolio allocation of 2-5% suits risk-tolerant mandates, balancing tech-heavy DAX positions.

Institutional moves, like Moore Capital trimming holdings, signal profit-taking but not conviction loss. Retail interest via social sentiment tools indicates broadening awareness.

Risks and Open Questions Ahead

Competition intensifies from rivals like UCB and Janssen in FcRn space, pressuring market share. Myositis trial risks loom, with negative data potentially halving expansion value.

Patent cliffs post-2030 necessitate pipeline success; manufacturing scale-up challenges persist. Macro headwinds, including US reimbursement scrutiny, could cap pricing.

Regulatory delays in Europe pose hurdles, though Argenx's track record mitigates. Volatility suits patient capital, not short-term trades.

DACH Investor Angle: European Biotech Champion

As a Dutch issuer with strong Benelux and German operations, Argenx resonates for DACH portfolios seeking EU-domiciled innovation. Proximity aids site visits and stakeholder engagement.

German-speaking investors benefit from clear EMA interactions and local KOL networks in autoimmune fields. Amid DAX biotech scarcity, ARGX fills a high-conviction gap.

Sustainability focus aligns with EU ESG mandates, enhancing institutional appeal. Long-term, DACH wealth managers view Argenx as a multi-year compounder.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.